WO2008048711A1 - Process for preparing oxymorphone - Google Patents
Process for preparing oxymorphone Download PDFInfo
- Publication number
- WO2008048711A1 WO2008048711A1 PCT/US2007/068009 US2007068009W WO2008048711A1 WO 2008048711 A1 WO2008048711 A1 WO 2008048711A1 US 2007068009 W US2007068009 W US 2007068009W WO 2008048711 A1 WO2008048711 A1 WO 2008048711A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxymorphone
- oripavine
- hydrogenation
- salt
- hydroxymorphinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Definitions
- This invention relates to preparation of opiates such as 14-hydroxymorphinone, oxymorphone and naloxone from oripavine.
- Oxymorphone a potent opiate analgesic, is a semi-synthetic substitute for morphine. It is about ten times as potent as morphine. In the United States, FDA has approved oxymorphone hydrochloride in oral, parenteral and suppository form. Naltrexone, methylnaltrexone, buprenorphine, nalmefene, nalorphine and naloxone are other useful opiates. [0004] Oxymorphone can also be converted to these and other useful compounds, such as nal- compounds, including naloxone.
- Oxymorphone is typically synthesized using thebaine, morphine or another compound as a starting material.
- Thebaine when used, is generally obtained from the concentrated poppy straw (CSP-T), a poppy extract relatively rich in thebaine.
- Reaction schemes for producing oxymorphone from thebaine take several steps, to intermediates such as oxycodone, then conversion of the 3-methoxy group of oxycodone to the 3-hydroxy group of oxymorphone.
- US Patent 6,291,675 discloses a method for O-demethylation of the 3-methoxy group of opiates by use of a lithium hydride compound, providing a yield of O-demethylated opioid of at least 23%.
- US Patent No. 5,922,876 discloses preparation of oxymorphone from morphine. The process includes protection of the 3 -hydroxy group of morphine with an aceto or benzyl group.
- Syntheses according to the present invention do not include the conversion of a 3- methoxy group present on opiates to a 3 -hydroxy group, and are therefore expected to result in increased reaction efficiencies, such as reduced reaction complexities and increased yield.
- oripavine can be economically converted to other opiates, such as oxymorphone and derivatives thereof.
- Any starting material comprising oripavine may be used.
- the starting material preferably comprises greater than about 50% by weight oripavine, preferably greater than about 70%, more preferably greater than about 95%.
- the starting material is preferably purified oripavine, or a concentrate of poppy straw comprising oripavine as the main alkaloid (CPS-O).
- the oripavine comprises "natural oripavine,” but can also comprise any source of oripavine.
- naturally oripavine is meant oripavine obtained directly from a natural source (e.g., botanical, bioengineered bacterial, etc.), and is meant to distinguish from oripavine obtained in a laboratory or factory setting by partial or total chemical synthesis, e.g., synthetic or semi-synthetic oripavine.
- Natural oripavine includes, without limitation, CPS-O, and purified oripavine obtained from CSP-O or other poppy straw.
- oripavine is oxidized with an oxidizing agent to obtain 14- hydroxymorphinone.
- the 14-hydroxymorphinone is then preferably reduced with a reducing agent to obtain oxymorphone.
- the 14-hydroxymorphinone can also be used in other ways, preferably to prepare other products.
- the oxidizing agent can comprise any oxidizing agent that permits the conversion of oripavine to 14-hydroxymorphinone, including, but not limited to, peroxy acids, such as performic acid, peracetic acid, and m-chloroperoxybenzoic acid (MCPBA). Mixtures of oxidizing agents may be used. When a peroxy acid is used, it may be added, or prepared in situ. [0011] When the oxidizing agent comprises a peroxy acid prepared in situ, it may be prepared in any manner, preferably by combining a peroxide and an acid. Any peroxide or combination of peroxides that can provide a peroxy acid can be used, preferably hydrogen peroxide, for example, aqueous hydrogen peroxide.
- Any acid or combination of acids that can provide a peroxy acid can be used, preferably formic acid, or acetic acid, for example, aqueous solutions of formic and/or acetic acid.
- Performic acid may be obtained, for example, by combining hydrogen peroxide and formic acid, and peracetic acid may be obtained by combining hydrogen peroxide with acetic acid.
- the reaction may be carried out in any appropriate solvent, preferably an aqueous solvent.
- the oxidizing agent includes a peroxy acid, it is preferred to use a solvent comprising the corresponding acid.
- the oxidizing agent comprises performic acid, it is preferred to use a solvent comprising formic acid, and when the oxidizing agent comprises peracetic acid, it is preferred to use a solvent comprising acetic acid.
- MCPBA MCPBA is used, it is preferred to use a solvent comprising acetic acid.
- An exemplary process using performic acid as oxidizing agent is:
- any temperature that permits the reaction to proceed may be used.
- the temperature need not remain constant, and may vary during the reaction. Higher reaction temperatures speed up the reaction, but may increase formation of by-products. Different oxidation agents may run optimally at different temperatures.
- Reactions employing performic acid for example are preferably run in the range of about 20 to 60 0 C, more preferably about 40-50 0 C, even more preferably at about 50° C.
- Reactions employing MCPBA are preferably run in the range of about 0 to 40 0 C, more preferably about 10-30 0 C, even more preferably at about ambient temperature, e.g., about 25° C.
- the reaction is run under conditions to convert oripavine to 14-hydroxymorphinone.
- at least about 90% of the oripavine is converted to 14-hydroxymorphinone, more preferably, about 95%, even more preferably about 98% or 99%.
- the conversion of oripavine to 14-hydroxymorphinone will be about 100%.
- the remaining amount of oripavine in the reaction mixture, as well as the amount of 14-hydroxymorphinone produced can be determined by any method, preferably by TLC or HPLC.
- Any reducing agent may be used to convert 14-hydroxymorphinone to oxymorphone.
- Catalytic hydrogenation is a preferred method, e.g., with palladium catalyst, preferably Pd/C.
- Catalytic hydrogenation may be performed at any suitable pressure, and is preferably done completely, or in part, in a low pressure environment. Catalytic hydrogenation preferably includes hydrogenation at or greater than, about 1 atmosphere pressure. By "low pressure" is preferably meant less than about 10 atm, or less than about 4 atm. Catalytic hydrogenation reactions, therefore, include hydrogenation at, e.g., at about 1-10 or about 1-4 atm. Low pressure hydrogenation generally requires less expensive processing and/or lower equipment costs than hydrogenation at higher pressures.
- the oxidizing and reduction may be performed as a "one pot" process, or may be done in separate vessels.
- the 14-hydroxymorphinone may be isolated, but need not be isolated, prior to reduction. In a preferred embodiment, the 14-hydroxymorphinone is not isolated in solid form prior to reduction.
- the opiate e.g., oxymorphone, or a salt thereof
- a salt preferably the hydrochloride salt.
- An exemplary process for purifying crude oripavine base is:
- Purification aids may be used in the purification process.
- Preferred purification aids include adsorbents.
- Some preferred purification aids include activated carbon (commercially available as, e.g., Darco), and/or powdered cellulose (commercially available as, e.g., Solka- Floc).
- the reducing agent sodium bisulfite may be used, e.g., when performing the reaction in the presence of oxidants, e.g., under an oxidizing atmosphere. When the reaction is run under a non-oxidizing atmosphere, e.g., nitrogen gas, it may be possible to omit sodium bisulfite.
- Other purification aids including purification aids known in the art, may be selected and used by a person of ordinary skill in the art.
- Opiate salts e.g., of oxymorphone may also be prepared. Any salt, preferably a therapeutically acceptable salt, is included in the present invention.
- the hydrochloride is a preferred salt. Methods for preparing salts of compounds are known in the art. An exemplary process for preparing the hydrochloride salt of purified oxymorphone is:
- oxymorphone preferably purified oxymorphone
- a liquid preferably an alcohol and/or water; and more preferably ethanol, 2-propanol, combinations thereof, and combinations with water.
- an acid such as hydrochloric acid (preferably concentrated or gaseous HCl)
- hydrochloric acid preferably concentrated or gaseous HCl
- Oxymorphone, or salt thereof, preferably oxymorphone HCl may be prepared into pharmaceutical dosage forms.
- Pharmaceutical dosage forms include, but are not limited to, tablets, pills, capsules (including hard or soft gelatin capsules), parenteral formulations, suppositories, patches and powders.
- a salt e.g., the hydrochloride
- Oxymorphone base may be used, e.g., for transdermal patches.
- Preferred dosage forms include parenteral formulations and suppositories.
- Oxymorphone can also be converted to other compounds, such as naloxone. Methods for effecting this conversion are known in the art.
- Oripavine (50.0 g, 168 mmol), de-ionized water (70 ml) and 90% formic acid (42.0 g, 0.821 mol) are charged into a 500 ml 3-necked round bottom flask. The solution is stirred at 30- 40° C and to the composition is added 35% hydrogen peroxide drop-wise (19.7 g, 0.203 mol) while keeping the temperature below 40° C. Upon completion of the addition, the mixture is stirred at 40-50° C for 4 hours. The reaction mixture is transferred to a 1-L hydrogenation vessel and 5% Pd/C (3.2 g) and 2-propanol (160 ml) are added.
- Hydrogenation proceeds at 46-52 psig at room temperature overnight (about 18 h).
- the catalyst in the mixture is filtered off.
- the filtrate and washings are combined and basified with 50% NaOH (59.6 g) to pH 9.16.
- the temperature is kept at below 30° C during the basification.
- the slurry is stirred at room temperature for 1 hour, and filtered to give a brown solid, which is then dried at 90° C and 25" Hg vacuum overnight to provide the crude oxymorphone as light brown solids (48.2 g, 160 mmol, 95.2% yield).
- Oripavine (50.0 g, 168 mmol), is converted to 14-hydroxymorphinone as in Example 2 through and including addition of hydrogen peroxide. Upon completion of the addition, the mixture is stirred at 40-50° C. By HPLC, it is determined that the area ratio of 14- hydroxymorphinone: oripavine is 27 '.2:72.8 after 1 hour, and 99.3:0.7 after 4 hours. After 4 hours 40 minutes, the reaction mixture is transferred to a 1-L hydrogenation vessel and 5% Pd/C (3.2 g) (Degussa ElOl o/w, H 2 O 56.2%) is added. Hydrogenation proceeds at 46-52 psig at room temperature overnight (about 18 h).
- the mixture is filtered, and rinsed with about 50 ml water. 250 ml of filtrate are obtained, to which is added 25 ml butanol, yielding a mixture having pH of 2.86. While kept at less than 30° C, or at about 19.6° C, the filtrate is basified with 57.5 g of 50% NaOH, resulting in a pH of 9.05. The mixture is stirred for about one hour at room temperature, filtered, washed with water (4 x 50 ml), yielding a brown solid. The wet cake is dried at 93° C at 25" Hg overnight, yielding 44.2 g, 87.2% yield, of oxymorphone as a light brown solid.
- a mixture of CPS-O (6.92 g contains 76% (5.26 g, 17.7 m mol) of oripavine), meta- chloroperoxybenzoic acid (MCPBA, 4.30 g) and glacial acetic acid (52 ml) is stirred at room temperature for 5 hours. The amount of oripavine is then expected to be not more than 1% by HPLC analysis. To the resulting 14-hydroxymorphinone mixture is added 5% Pd/C (0.55 g) and hydrogenation proceeds at room temperature at 48 psig of hydrogen for about 18 hours. The amount of unreacted 14-hydroxymorphinone is expected to be not more than 0.5% by HPLC analysis.
- the mixture is filtered to remove the catalyst and the filtrate is evaporated to almost dryness.
- the residue is dissolved in water and basified to pH 9 by ammonium hydroxide.
- the solids are collected by filtration and dried at 90° C and under 25-inch Hg of vacuum for 3 hours to give crude oxymorphone (approximately 95% yield expected).
- Tartaric acid (5.5 g) is added to adjust the pH to 4.35 to complete dissolution.
- Darco (1.0 g) and Solka-floc (1.0 g) are added and stirred at 45-55° C for 1 hour.
- the mixture is filtered and rinsed with water (10 ml).
- the filtrate and washings are combined and to this are added Darco (1.0 g), Solka-floc (1.0 g) and sodium bisulfite (0.4 g).
- the mixture is stirred for 1 hour at 45-55° C, filtered and rinsed with water (10 ml).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07840163A EP2073636B1 (en) | 2006-10-17 | 2007-05-02 | Process for preparing oxymorphone |
DK07840163.5T DK2073636T3 (en) | 2006-10-17 | 2007-05-02 | PROCEDURE FOR MANUFACTURING OXYMORPHONE |
CA2674915A CA2674915C (en) | 2006-10-17 | 2007-05-02 | Process for preparing oxymorphone |
AU2007313103A AU2007313103C1 (en) | 2006-10-17 | 2007-05-02 | Process for preparing oxymorphone |
ES07840163T ES2392594T3 (en) | 2006-10-17 | 2007-05-02 | Procedure for preparing oxymorphone |
US12/446,171 US8134002B2 (en) | 2006-10-17 | 2007-05-02 | Process for preparing oxymorphone |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82981706P | 2006-10-17 | 2006-10-17 | |
US60/829,817 | 2006-10-17 | ||
US61104906A | 2006-12-14 | 2006-12-14 | |
US11/611,049 | 2006-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008048711A1 true WO2008048711A1 (en) | 2008-04-24 |
Family
ID=39314340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/068009 WO2008048711A1 (en) | 2006-10-17 | 2007-05-02 | Process for preparing oxymorphone |
Country Status (6)
Country | Link |
---|---|
US (1) | US8134002B2 (en) |
EP (1) | EP2073636B1 (en) |
AU (1) | AU2007313103C1 (en) |
DK (1) | DK2073636T3 (en) |
ES (1) | ES2392594T3 (en) |
WO (1) | WO2008048711A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008118654A1 (en) * | 2007-03-23 | 2008-10-02 | Mallinckrodt Inc. | Improved preparation of oxymorphone from oripavine |
WO2011117172A1 (en) | 2010-03-23 | 2011-09-29 | Siegfried Ltd. | Preparation of low impurity opiates in a continuous flow reactor |
US8309727B2 (en) | 2007-04-16 | 2012-11-13 | Mallinckrodt Llc | Opiate reduction utilizing catalytic hydrogen transfer reaction |
WO2012163796A1 (en) * | 2011-05-27 | 2012-12-06 | Grünenthal GmbH | Crystalline, anhydrous forms of oxymorphone hydrochloride |
EP2590649A1 (en) * | 2010-07-08 | 2013-05-15 | Alkermes Pharma Ireland Limited | Process for the synthesis of substituted morphinans |
WO2013188418A1 (en) | 2012-06-11 | 2013-12-19 | Jianguang Sun | Improved method of preparing oxymorphone |
US9126977B2 (en) | 2010-08-23 | 2015-09-08 | Alkermes Pharma Ireland Limited | Methods for treating antipsychotic-induced weight gain |
US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
WO2016123202A1 (en) | 2015-01-29 | 2016-08-04 | Johnson Matthey Public Limited Company | Process of preparing low abuk oxymorphone hydrochloride |
EP3252055A1 (en) | 2016-05-31 | 2017-12-06 | Alcaliber Investigacion Desarrollo e Innovacion, S.L. | Process for obtaining 3,14-diacetyloxymorphone from oripavine |
RU2707560C2 (en) * | 2015-03-25 | 2019-11-28 | Тайвань Фармасьютикалз Ко., Лтд. | Antagonists of tol-like receptor 4 and use in autoimmune liver diseases |
US11707466B2 (en) | 2020-11-12 | 2023-07-25 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2644095A1 (en) * | 2006-03-02 | 2007-09-13 | Mallinckrodt Inc. | Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds |
CA2674915C (en) | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
EP2580218B1 (en) | 2010-06-11 | 2015-02-25 | Rhodes Technologies | Process for n-dealkylation of tertiary amines |
CA2936749C (en) | 2010-06-11 | 2019-07-09 | Joshua R. Giguere | Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof |
US8563571B2 (en) | 2010-07-22 | 2013-10-22 | Noramco, Inc. | Crystalline forms of oxymorphone hydrochloride |
WO2012151669A1 (en) | 2011-05-06 | 2012-11-15 | Brock University | Process for the preparation of morphine analogs via metal catalyzed n-demethylation/functionalization and intramolecular group transfer |
CN105452253A (en) | 2013-08-02 | 2016-03-30 | 庄信万丰股份有限公司 | Process for preparation of oxymorphone |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002529A1 (en) * | 1997-07-11 | 1999-01-21 | Penick Corporation | Preparation of oxymorphone, oxycodone and derivatives |
WO2005028483A1 (en) * | 2003-09-22 | 2005-03-31 | Glaxosmithkline Australia Pty Ltd | Process for the synthesis of morphinane compounds and intermediates thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3474101A (en) | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
GB1317210A (en) | 1970-12-11 | 1973-05-16 | Macarlan Smith Ltd | Reduction of thebaine |
FR2636330B1 (en) | 1988-09-13 | 1990-11-30 | Sanofi Sa | PROCESS FOR THE PREPARATION OF MORPHINANE DERIVATIVES |
PT95069B (en) | 1989-08-24 | 1997-10-31 | Searle & Co | PROCESS FOR THE PREPARATION OF (+) - ISOMERS OF DERIVATIVES OF ENDOETANO / ENDOETANOEPOXIMOFINANO, UTEIS AS ANTI-TUSTIC AGENTS |
US6291675B1 (en) | 1996-05-21 | 2001-09-18 | The United States As Represented By The Department Of Health And Human Services | Methods of o-demethylation and n-deprotection |
US6067749A (en) | 1996-07-11 | 2000-05-30 | Tasmanian Alkaloids Pty. Ltd. | Papaver somniferum strain with high concentration of thebaine and oripavine |
KR20000016052A (en) | 1997-03-27 | 2000-03-25 | 히라이 가쯔히꼬 | Morphinane derivatives and medicinal use thereof |
GB9713703D0 (en) | 1997-06-30 | 1997-09-03 | Johnson Matthey Plc | Preparation of opiates |
US6177567B1 (en) | 1999-10-15 | 2001-01-23 | Boehringer Ingelheim Chemicals, Inc. | Method for preparing oxycodone |
US6864370B1 (en) | 2003-06-05 | 2005-03-08 | Zhaiwei Lin | Process for manufacturing oxycodone |
US7875718B2 (en) | 2003-09-22 | 2011-01-25 | Johnson Matthey Public Limited Company | Process for the synthesis of morphinane compounds and intermediates thereof |
TWI483944B (en) * | 2004-03-30 | 2015-05-11 | Euro Celtique Sa | Oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oral dosage form,and pharmaceutically acceptable package having less than 25 ppm 14-hydroxycodeinone |
GB2429206A (en) | 2004-07-09 | 2007-02-21 | Tasmanian Alkaloids Pty Ltd | Process for the synthesis of hydromorphone |
GB0421149D0 (en) | 2004-09-23 | 2004-10-27 | Johnson Matthey Plc | Preparation of oxycodone |
WO2006084389A1 (en) * | 2005-02-11 | 2006-08-17 | Cilag Ltd. | Method for purifying noroxymorphone compounds |
CA2644095A1 (en) | 2006-03-02 | 2007-09-13 | Mallinckrodt Inc. | Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds |
CA2674915C (en) * | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
GB0624880D0 (en) * | 2006-12-14 | 2007-01-24 | Johnson Matthey Plc | Improved method for making analgesics |
EP2342207B1 (en) * | 2008-09-30 | 2015-11-11 | Mallinckrodt LLC | Processes for the alkylation of norbuprenorphine with reduced impurity formation |
-
2007
- 2007-05-02 EP EP07840163A patent/EP2073636B1/en active Active
- 2007-05-02 US US12/446,171 patent/US8134002B2/en active Active
- 2007-05-02 ES ES07840163T patent/ES2392594T3/en active Active
- 2007-05-02 DK DK07840163.5T patent/DK2073636T3/en active
- 2007-05-02 AU AU2007313103A patent/AU2007313103C1/en active Active
- 2007-05-02 WO PCT/US2007/068009 patent/WO2008048711A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002529A1 (en) * | 1997-07-11 | 1999-01-21 | Penick Corporation | Preparation of oxymorphone, oxycodone and derivatives |
WO2005028483A1 (en) * | 2003-09-22 | 2005-03-31 | Glaxosmithkline Australia Pty Ltd | Process for the synthesis of morphinane compounds and intermediates thereof |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8217175B2 (en) | 2007-03-23 | 2012-07-10 | Mallinckrodt Llc | Preparation of oxymorphone from oripavine |
WO2008118654A1 (en) * | 2007-03-23 | 2008-10-02 | Mallinckrodt Inc. | Improved preparation of oxymorphone from oripavine |
US8309727B2 (en) | 2007-04-16 | 2012-11-13 | Mallinckrodt Llc | Opiate reduction utilizing catalytic hydrogen transfer reaction |
AU2011231748B2 (en) * | 2010-03-23 | 2013-11-14 | Siegfried Ag | Preparation of low impurity opiates in a continuous flow reactor |
EP2377866A1 (en) | 2010-03-23 | 2011-10-19 | Siegfried Ltd. | Preparation of low impurity opiates in a continuous flow reactor |
WO2011117172A1 (en) | 2010-03-23 | 2011-09-29 | Siegfried Ltd. | Preparation of low impurity opiates in a continuous flow reactor |
US20130035489A1 (en) * | 2010-03-23 | 2013-02-07 | Siegfried Ag | Preparation of low impurity opiates in a continuous flow reactor |
US8921557B2 (en) | 2010-03-23 | 2014-12-30 | Siegfried Ag | Preparation of low impurity opiates in a continuous flow reactor |
EP2590649A4 (en) * | 2010-07-08 | 2014-01-29 | Alkermes Pharma Ireland Ltd | Process for the synthesis of substituted morphinans |
US10155772B2 (en) | 2010-07-08 | 2018-12-18 | Alkermes Pharma Ireland Limited | Process for the synthesis of substituted morphinans |
EP2590649A1 (en) * | 2010-07-08 | 2013-05-15 | Alkermes Pharma Ireland Limited | Process for the synthesis of substituted morphinans |
US10005790B2 (en) | 2010-07-08 | 2018-06-26 | Alkermes Pharma Ireland Limited | Process for the synthesis of substituted morphinans |
US9126977B2 (en) | 2010-08-23 | 2015-09-08 | Alkermes Pharma Ireland Limited | Methods for treating antipsychotic-induced weight gain |
US9926328B2 (en) | 2011-05-27 | 2018-03-27 | Endo Pharmaceuticals Inc. | Crystalline, anhydrous forms of oxymorphone hydrochloride |
US8969368B2 (en) | 2011-05-27 | 2015-03-03 | Grünenthal GmbH | Crystalline, anhydrous forms of oxymorphone hydrochloride |
WO2012163796A1 (en) * | 2011-05-27 | 2012-12-06 | Grünenthal GmbH | Crystalline, anhydrous forms of oxymorphone hydrochloride |
US9440986B2 (en) | 2011-05-27 | 2016-09-13 | Endo Pharmaceuticals Inc. | Crystalline, anhydrous forms of oxymorphone hydrochloride |
US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
US9657029B2 (en) | 2012-06-11 | 2017-05-23 | Siegfried Generics International Ag | Method of preparing oxymorphone |
WO2013188418A1 (en) | 2012-06-11 | 2013-12-19 | Jianguang Sun | Improved method of preparing oxymorphone |
CN107428767A (en) * | 2015-01-29 | 2017-12-01 | 庄信万丰股份有限公司 | The method for preparing low ABUK oxymorphones hydrochloride |
JP2018507193A (en) * | 2015-01-29 | 2018-03-15 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニーJohnson Matthey Public Limited Company | Process for preparing low ABUK oxymorphone hydrochloride |
US9918979B2 (en) | 2015-01-29 | 2018-03-20 | Johnson Matthey Public Limited Company | Process of preparing low ABUK oxymorphone hydrochloride |
WO2016123202A1 (en) | 2015-01-29 | 2016-08-04 | Johnson Matthey Public Limited Company | Process of preparing low abuk oxymorphone hydrochloride |
CN107428767B (en) * | 2015-01-29 | 2019-06-18 | 庄信万丰股份有限公司 | The method for preparing low ABUK oxymorphone hydrochloride |
RU2707560C2 (en) * | 2015-03-25 | 2019-11-28 | Тайвань Фармасьютикалз Ко., Лтд. | Antagonists of tol-like receptor 4 and use in autoimmune liver diseases |
EP3252055A1 (en) | 2016-05-31 | 2017-12-06 | Alcaliber Investigacion Desarrollo e Innovacion, S.L. | Process for obtaining 3,14-diacetyloxymorphone from oripavine |
WO2017207519A1 (en) | 2016-05-31 | 2017-12-07 | Alcaliber Investigación Desarrollo E Innovación, S.L. | Process for obtaining 3,14-diacetyloxymorphone from oripavine |
US11707466B2 (en) | 2020-11-12 | 2023-07-25 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
US11951111B2 (en) | 2020-11-12 | 2024-04-09 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
Also Published As
Publication number | Publication date |
---|---|
ES2392594T3 (en) | 2012-12-12 |
AU2007313103B2 (en) | 2012-09-13 |
US8134002B2 (en) | 2012-03-13 |
US20110009634A1 (en) | 2011-01-13 |
AU2007313103C1 (en) | 2014-01-30 |
DK2073636T3 (en) | 2012-11-19 |
AU2007313103A1 (en) | 2008-04-24 |
EP2073636B1 (en) | 2012-09-05 |
EP2073636A1 (en) | 2009-07-01 |
EP2073636A4 (en) | 2009-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2073636B1 (en) | Process for preparing oxymorphone | |
CA2674915C (en) | Process for preparing oxymorphone | |
US8357802B2 (en) | Process for preparing oxymorphone | |
AU2009233315B2 (en) | An improved process for the preparation of morphinane analogues | |
EP1658293B1 (en) | A method of preparation of oxycodone | |
CA2539659C (en) | Process for the synthesis of morphinane compounds and intermediates thereof | |
US8106201B2 (en) | Process for the synthesis of morphinane compounds and intermediates thereof | |
AU2012216358B2 (en) | Process For Preparing Oxymorphone, Naltrexone and Buprenorphine | |
AU2004274038B2 (en) | Process for the synthesis of morphinane compounds and intermediates thereof | |
WO2017207519A1 (en) | Process for obtaining 3,14-diacetyloxymorphone from oripavine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07840163 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007313103 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2007313103 Country of ref document: AU Date of ref document: 20070502 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2674915 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007840163 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12446171 Country of ref document: US |